anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The use of prophylactic antibiotics in surgery is contentious. With the rise in antimicrobial resistance, evidence-based antibiotic use should be followed. This systematic review and network meta-analysis will assess the effectiveness of different antibiotics on the prevention of surgical site infection (SSI) following hand trauma surgery.
METHODS AND ANALYSIS: The databases Embase, MEDLINE, CINAHL and CENTRAL, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform will be searched. Abstracts will be screened by two persons independently to identify eligible studies. This systematic review will include both randomised and non-randomised prospective comparative studies in participants with hand and/or wrist injuries requiring surgery; bite injuries will be excluded. The network meta-analysis will compare the use of different prophylactic antibiotics against each other, placebo and/or no antibiotics on the development of SSI within 30 days of surgery (or 90 days if there is an implanted device). The Cochrane risk-of-bias tool 2 will be used to assess the risk of methodological bias in randomised controlled trials, and the Newcastle-Ottowa scale (NOS) will be used to assess the risk of bias in non-randomised studies. A random-effects network meta-analysis will be conducted along with subgroup analyses looking at antibiotic timing, injury type, and operation location. Sensitivity analyses including only low risk-of-bias studies will be conducted, and the confidence in the results will be assessed using Confidence in Network Meta-Analysis (CINEMA).
DISCUSSION: This systematic review and network meta-analysis aims to provide an up-to-date synthesis of the studies assessing the use of antibiotics following hand and wrist trauma to enable evidence-based peri-operative prescribing.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023429618.
The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
Novel approaches are needed to improve adherence to combination antiretroviral therapy. Nonadherence can lead to reduced drug levels and inadequate viral suppression, which accelerates drug resistance. Thus nonadherence in the first few months of primary HIV infection can limit therapeutic options for an individual years later. Barriers to optimal treatment adherence in patients with early HIV infection include complex treatment regimens which disrupt daily routines, drug intolerance, and concomitant illness including depression. Directly observed therapy has been successful in improving overall effectiveness of antituberculosis therapy and may be a useful strategy in HIV-infected patients.

All patients receive combination antiretroviral therapy with didanosine (ddI), stavudine (d4T), efavirenz (EFV), and nelfinavir (NFV). Patients are randomized to self-administered (SAT) versus observed (MAT) therapy for 24 weeks. Patients randomized to MAT receive one directly observed dose (ddI, d4T, EFV, and NFV) of their antiretroviral regimen by a field worker or nurse at the clinic 5 days per week. As a reminder for the second NFV and d4T dose, MAT patients are provided with an alarm watch programmed to sound at dosing times. The alarm watch also serves as a reminder for weekend doses that will not be directly observed. Patients randomized to SAT receive standard care. All patients are monitored with monthly plasma HIV RNA levels and CD4 and CD8 cell counts. At Week 24, all patients are crossed over to SAT for an additional 48 weeks of follow-up.
This is a multi-center, randomized, controlled intervention clinical trial. A total of 1,000 current smokers ( ≥ 10 pack-years) with rapid decline in lung function will be recruited from Predictive Value of Inflammatory Biomarkers and FEV1 for COPD (PIFCOPD) study (clinical trails. gov ID NCT03532893) after 1 year of follow-up. Subjects will be qually divided into two groups, comprehensive smoking cessation intervention group (early health warning intervention combined with brief smoking cessation intervention) and brief smoking cessation intervention group. Health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 9 units participating in the study, include the The Second Hospital of Hebei Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial Hospital Affiliated to Shandong University, Shan xi Dayi Hospital（Shanxi Academy of Medical Sciences）, Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia University. Some questionnaire about tobacco dependence, depression, anxiety, the willingness to quit smoking and withdrawal symptoms will be collected. Exhaled CO will be measured. Subjects will recived 6 times of smoking cessation intervention in 6 month and followed in another 6 month. The primary outcome is the rate of quitting smoking. The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2019-255). Any protocol modifications will be submitted for the IRB review and approval.
OBJECTIVE: Machine learning and deep learning techniques offer a promising multidisciplinary solution for subarachnoid hemorrhage (SAH) detection. The novel transfer learning approach mitigates the time constraints associated with the traditional techniques and demonstrates a superior performance. This study aims to evaluate the effectiveness of convolutional neural networks (CNNs) and CNN-based transfer learning models in differentiating between aneurysmal SAH and nonaneurysmal SAH.
METHODS: Data from Istanbul Ümraniye Training and Research Hospital, which included 15,600 digital imaging and communications in medicine images from 123 patients with aneurysmal SAH and 7793 images from 80 patients with nonaneurysmal SAH, were used. The study employed 4 models: Inception-V3, EfficientNetB4, single-layer CNN, and three-layer CNN. Transfer learning models were customized by modifying the last 3 layers and using the Adam optimizer. The models were trained on Google Collaboratory and evaluated based on metrics such as F-score, precision, recall, and accuracy.
RESULTS: EfficientNetB4 demonstrated the highest accuracy (99.92%), with a better F-score (99.82%), recall (99.92%), and precision (99.90%) than the other methods. The single- and three-layer CNNs and the transfer learning models produced comparable results. No overfitting was observed, and robust models were developed.
CONCLUSIONS: CNN-based transfer learning models can accurately diagnose the etiology of SAH from computed tomography images and is a valuable tool for clinicians. This approach could reduce the need for invasive procedures such as digital subtraction angiography, leading to more efficient medical resource utilization and improved patient outcomes.
The present invention relates to an anticancer slow-released injection containing vasoinhibitor. It is formed from slow-released microsphere and solvent. The slow-released microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is special solvent containing suspension adjuvant. The anticancer effective component is vasoinhibitor selected from gemfitine, elotine, pelitine, thalidomide, vascular inhibine, endothelium inhibine, smasni, awasdine, kanatine or panitoma, etc. and/or cytotoxin medicine selected from antimitotic medicine, anticancer antibiotic and/or antimetabolite medicine. The slow-released auxiliary material is selected from polylactic acid and its copolymer, monomethyl polyethylene glycol/polylactic acid copolymer, polyethylene glycol/polylactic acid copolymer. sebacic acid and its copolymer and EVAc, etc. The suspension adjuvant is selected from carboxymethyl cellulose sodium, etc. and its viscosity is 10 cp-3000 cp (20 deg.C-30 deg.C). The slow-released microsphere also can be made into slow-released, implant preparation.
OBJECTIVES: To develop an artificial intelligence (AI) tool with automated pancreas segmentation and measurement of pancreatic morphological information on CT images to assist improved and faster diagnosis in acute pancreatitis.
METHODS: This study retrospectively contained 1124 patients suspected for AP and received non-contrast and enhanced abdominal CT examination between September 2013 and September 2022. Patients were divided into training (N = 688), validation (N = 145), testing dataset [N = 291; N = 104 for normal pancreas, N = 98 for AP, N = 89 for AP complicated with PDAC (AP&PDAC)]. A model based on convolutional neural network (MSAnet) was developed. The pancreas segmentation and measurement were performed via eight open-source models and MSAnet based tools, and the efficacy was evaluated using dice similarity coefficient (DSC) and intersection over union (IoU). The DSC and IoU for patients with different ages were also compared. The outline of tumour and oedema in the AP and were segmented by clustering. The diagnostic efficacy for radiologists with or without the assistance of MSAnet tool in AP and AP&PDAC was evaluated using receiver operation curve and confusion matrix.
RESULTS: Among all models, MSAnet based tool showed best performance on the training and validation dataset, and had high efficacy on testing dataset. The performance was age-affected. With assistance of the AI tool, the diagnosis time was significantly shortened by 26.8% and 32.7% for junior and senior radiologists, respectively. The area under curve (AUC) in diagnosis of AP was improved from 0.91 to 0.96 for junior radiologist and 0.98 to 0.99 for senior radiologist. In AP&PDAC diagnosis, AUC was increased from 0.85 to 0.92 for junior and 0.97 to 0.99 for senior.
CONCLUSION: MSAnet based tools showed good pancreas segmentation and measurement performance, which help radiologists improve diagnosis efficacy and workflow in both AP and AP with PDAC conditions.
ADVANCES IN KNOWLEDGE: This study developed an AI tool with automated pancreas segmentation and measurement and provided evidence for AI tool assistance in improving the workflow and accuracy of AP diagnosis.
This study will have two stages. Stage 1: Dose escalation, about 9-18 subjects, who are either refractory to induction therapy or have relapsed (R/R) after achieving remission with prior therapy will be recruited. The enrolled subjects will receive Mitoxantrone Hydrochloride Liposome injection in one of three dose-escalation (30 mg/m\^2, 36 mg/m\^2, 40 mg/m\^2) by intravenous infusion (IV), every 28 days (q4w, 1 cycle). If the patient achieves remission (at least PR) after at most 2 cycles of induction, the original regimen of consolidation therapy can be continued for 2-4 cycles, with a total course of no more than 6 cycles. The DLT observation period is 28 days after the first dose in cycle 1, and including the first 28 days treatment cycle. Subjects in Cycle 1 will have PK sampling performed. Stage 2: Dose expansion, about 35-72 subjects with R/R AML or unfit AML will be recruited. The subjects will receive Mitoxantrone Hydrochloride Liposome dose according to the results of stage 1. If the patient achieves remission (at least PR) after at most 2 cycles of induction, the original regimen of consolidation therapy can be continued for 2-4 cycles, with a total course of no more than 6 cycles.
NEW MATERIAL:A compound expressed by formula I. USE:An intermediate for synthesizing forskolin of 100% optical purity. PREPARATION:A compound expressed by formula II is initially reacted with a compound expressed by formula III in the presence of a borane-THF complex in THF to provide a compound expressed by formula IV, which is then propargylated and refluxed in tert. butyl alcohol in the presence of potassium tert. butoxide while being heated. The obtained product is subsequently treated with camphor-10-sulfonic acid and then treated with the borane-THF complex to afford a compound expressed by formula V, which is further oxidized with pyridinium chlorometachromate and subsequently epimerized with NaOCH3 in methanol. The resultant compound expressed by formula VI is finally successively phenylselenylated and oxidized with hydrogen peroxide and the obtained product is then treated with boron trifluoride-ether and metachloroperbenzoic acid.
OBJECTIVE: To investigate the association between particulate matter and the incidence, disability, and mortality of stroke, we reported the burden of stroke attributable to particulate matter (PM2.5) pollution, including ambient particulate matter pollution (APMP) and household air pollution from solid fuels (HAP), from 1990 to 2019.
METHODS: We retrieved the detailed data on the burden of stroke attributable to PM2.5 from the Global Burden of Disease (GBD) 2019. The number of disability-adjusted life-years (DALYs) and deaths, age-standardized death rates (ASMR), and age-standardized disability-adjusted life-years rates (ASDR) attributable to PM2.5 were estimated by age, sex, geographical location, socio-demographic index (SDI), and stroke subtypes (ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage). The estimated annual percentage change (EAPC) was calculated to assess the trends in ASDR and ASMR during the period 1990-2019.
RESULTS: Regarding stroke subtypes, the proportion of ischemic stroke burden is increasing, while intracerebral hemorrhage carries the heaviest burden. Both APMP and HAP contributed the most to stroke-related deaths and DALYs of stroke among the elderly populations and males. The highest ASDR and ASMR of stroke attributable to APMP were in the middle SDI regions, especially in East Asia. For HAP, the highest ASDR and ASMR were in the low SDI regions, mainly in Oceania. From 1990-2019, in terms of the EAPC results, APMP caused an increased burden of stroke, whereas the impact of HAP significantly fell. The most pronounced increase in ASDR and ASMR for strokes attributed to APMP were in the low-middle SDI and low SDI regions, particularly among the 25-35 age group.
CONCLUSIONS: Stroke attributed to PM2.5 is a global health problem, and the patterns and trends were heterogeneous across APMP and HAP. Targeted interventions should be formulated for APMP and HAP.
PCT No. PCT/FR90/00274 Sec. 371 Date Feb. 11, 1991 Sec. 102(e) Date Feb. 11, 1991 PCT Filed Apr. 13, 1990 PCT Pub. No. WO90/12875 PCT Pub. Date Nov. 1, 1990The present invention relates to nucleotide sequences of Actinomycetales, in particular of mycobacteria, to oligonucleotides contained within said nucleotide sequences, to their uses as primers for the synthesis of Actinomycetales DNA and as probes for the detection of DNA and/or the transcription products of Actinomycetales, in particular of mycobacteria, to the products of expression of said sequences, to their uses and to antibodies directed towards the said products, to a method for detecting and identifying Actinomycetales and its uses, as well as to immunogenic compositions comprising the said expression products.
Provided are a method for preparing a highly concentrated fibrinogen solution, and a method for preparing a fibrin sealant component 1 containing the highly concentrated fibrinogen solution and Factor Î§III. More particularly, the method for preparing a highly concentrated fibrinogen solution according to the present invention can be prepared by adding amino acid or amino acid derivatives, and/or salts, etc. to a lowly concentrated fibrinogen solution separated from blood plasma and highly concentrating fibrinogen using an ultra filtration method, and a fibrin sealant component 1 in order to be used in a fibrin sealant product can be prepared by adding Factor Î§III before or after the ultra filtration in the method for preparing the highly concentrated fibrinogen. The fibrin sealant component 1 prepared by the method according to the present invention may be cryopreserved in a liquid state, be preserved for a long time at room temperature, and be immediately applied to treatment without performing a reconstitution process. In addition, the present invention relates to a fibrin sealant product configured of the fibrin sealant component 1 and a fibrin sealant component 2 which is a solution containing thrombin and calcium chloride filled in a separate container. The fibrin sealant product according to the present invention may be provided in a vial type in which the fibrin sealant component 1 and the fibrin sealant component 2 are filled in separate vials, respectively, or a pre-filled type in which the fibrin sealant component 1 and the fibrin sealant component 2 are filled in separate syringes connected with each other to thereby be immediately used.
The invention provides an enzymolysis-resistant antibacterial peptide I9H12, and a preparation method and application thereof. The sequence of the antibacterial peptide I9H12 is shown as the sequence table SEQ ID No. 1. The preparation method comprises the following steps: according to the amino acid properties, the enzyme cutting sites of main protease in vivo are avoided as much as possible, hydrophobic amino acid isoleucine (Ile) and positive charge amino acid histidine (His) are selected as main amino acids, I9H12 antibacterial peptide is newly designed, and the carboxyl terminal of the peptide is amidated to improve one positive charge and increase the stability of the peptide. The antibacterial peptide is applied to the preparation of targeted antibacterial drugs for treating gram-negative bacteria or fungal infectious diseases. The invention effectively improves the enzymolysis resistance of the antibacterial peptide and improves the potential of the antibacterial peptide in practical production.
Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the exosome-miRNA, transcriptome, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
The IBV Valve System (Spiration Inc. Redmond, WA) has CE Mark approval for the treatment of diseased and damaged lung. The devices are one-way valves that can be placed in the airways via flexible bronchoscopy limiting airflow distally. For the treatment of emphysema, valves are placed in airways communicating to the most diseased areas of lung tissue to re-direct airflow to less diseased areas. A multicenter, blinded and randomized study of these valves is being conducted in 7 centers in 6 European countries. The study is evaluating the effectiveness of this therapy for the treatment of upper lobe predominant emphysema in patients with severe to very severe emphysema (GOLD classification 3 to 4) that despite best medical management continue having poor quality of life, severe symptoms and physical limitations. The primary endpoints are to measure and compare responses using the St. George's Respiratory Questionnaire and lung volume changes as measured by CT-scans. Consented patients that meet the strict inclusion criteria have a bronchoscopic procedure and are randomized into treatment or control (no valves) groups. After the procedure, all patients stay blinded to their group assignment and have follow-up evaluations at 1 and 3 months. After the 3-month evaluation, each patient is un-blinded. The treatment group is then scheduled for an additional follow-up at 6 months and the control group is offered valve treatment (rollover) and evaluated approximately 3 months later.
Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
The present invention relates to the preparation of a liquid which can be provided in the following forms: lotion, fluid substance or oil. It relates to the treatment of the scalp, the strengthening of the hair root and the prevention or at least the reduction of hair loss. This preparation is obtained by heating to boiling temperature a mixture of the following elements in equal proportions: leaves, branches and fruits of cypress and swamp cypress, thuyas (Biota orientalis); Juniperus (Scopulorum or Skyrocket); Libocedrus (Calocedrus or Decurreus) of the Cupressceae family; Myrobalan; vinegar, until all the elements are completely cooked. The mixture is filtered. The basic product is ready for use. It needs only to be provided in one of the abovementioned forms (lotion, fluid or oil).
Acute abdominal pain is a very common chief complaint in the pediatric population, accounting for 5-10% of emergency department (ED) visits. Etiology differentiation is determined by complete history and physical examination, basic laboratory studies, and a variety of imaging study options. In this case report, we present an 8-year-old female with an unusual etiology of acute lower abdominal pain. She presented with tachycardia, hypertension, and bilateral lower quadrant abdominal tenderness without peritonitis. Laboratory studies were unremarkable and appendix ultrasound was indeterminate. CT with contrast revealed right ovarian vein thrombosis. Hematology evaluation did not reveal hypercoagulability. She was discharged on rivaroxaban, which was discontinued after a 3 month course and negative follow-up MRI. Ovarian vein thrombosis (OVT) most commonly develops in the peripartum time frame, with an estimated 20%-40% of cases not related to pregnancies. However, patients with nonpregnancy related OVT were determined to be significantly older than patients with pregnancy related OVT. This case report demonstrates the youngest documented case of OVT. This patient was not in the peripartum period and did not have any identifiable risk factors. Given this unprovoked OVT in a pediatric patient, in patients presenting with abdominal pain with unspecified etiology, advanced imaging studies may be helpful in establishing a diagnosis.
A light hardening tool for use in dentistry, comprises at least two light diodes and/or diode groups with differing spectral emission maxima. The tool polymerises a polymerisable material that contains a photo-initiator. The maximum spectral sensitivity of the photo initiator is different to the emission maxima of the primary light diode. <??>A light hardening tool for use in dentistry, comprises at least two light diodes and/or diode groups with differing spectral emission maxima. The tool polymerises a polymerisable material that contains a photo-initiator. The maximum spectral sensitivity of the photo initiator is different to the emission maxima of the primary light diode. <??>The emission spectrum of the first diode (12) partially overlaps the sensitivity spectrum of the photo initiator (20), while the emission spectrum of the second diode (14) has a greater overlap. <??>The sensitivity maxima of the photo-initiator is less than 20nm, especially less than 15nm from the second light diode emission maxima. The radiation intensity of the primary diode is at least 100mW/cm<2>. The dental material contains at least two photo initiators.
The specification describes aqueous gas microbubble dispersions.  The  gas micobubbles are stabilised by amphiphilic material consisting of phospholipid.  At least 75% of the  phospholipid comprises molecules which individually have an overall net charge.  The microbubbles exhibit advantageous stability, rendering them useful as efficacious contrast agents. An improved process for preparing microbubble-containing contrast agents is also disclosed.  The process comprises lyophilising an aqueous dispersion of gas microbubbles stabilised by one or more membrane-forming lipids to yield a dried product which may be reconstituted in an injectable carrier liquid to generate a microbubble-containing contrast agent.